Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced an inducement stock option grant. The Compensation Committee approved on March 17, 2025, options to purchase 7,500 shares of common stock for a new non-executive employee.
The stock options, granted under Nasdaq Rule 5635(c)(4), have a ten-year term and will vest in four equal annual installments. The exercise price matches the closing price of Autonomix's common stock on the Nasdaq Capital Market as of March 17, 2025. The grant serves as part of the employee's compensation package and was provided as an inducement for their employment.
Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici specializzata nella diagnostica e nelle tecnologie di trattamento delle malattie del sistema nervoso, ha annunciato un'assegnazione di opzioni su azioni come incentivo. Il Comitato Compensi ha approvato il 17 marzo 2025, opzioni per l'acquisto di 7.500 azioni ordinarie per un nuovo dipendente non esecutivo.
Le opzioni su azioni, concesse ai sensi della Regola 5635(c)(4) di Nasdaq, hanno una durata di dieci anni e matureranno in quattro rate annuali uguali. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni ordinarie di Autonomix sul Nasdaq Capital Market al 17 marzo 2025. L'assegnazione fa parte del pacchetto retributivo del dipendente ed è stata fornita come incentivo per il loro impiego.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos especializada en el diagnóstico y tratamiento de enfermedades del sistema nervioso, ha anunciado una concesión de opciones sobre acciones como incentivo. El Comité de Compensación aprobó el 17 de marzo de 2025, opciones para comprar 7,500 acciones ordinarias para un nuevo empleado no ejecutivo.
Las opciones sobre acciones, otorgadas bajo la Regla 5635(c)(4) de Nasdaq, tienen un plazo de diez años y se otorgarán en cuatro cuotas anuales iguales. El precio de ejercicio coincide con el precio de cierre de las acciones ordinarias de Autonomix en el Nasdaq Capital Market al 17 de marzo de 2025. La concesión forma parte del paquete de compensación del empleado y se proporcionó como un incentivo para su empleo.
Autonomix Medical (NASDAQ: AMIX)는 신경계 질환 진단 및 치료 기술을 전문으로 하는 의료기기 회사로, 유인 주식 옵션 부여를 발표했습니다. 보상 위원회는 2025년 3월 17일, 새로운 비임원 직원에게 7,500주를 구매할 수 있는 옵션을 승인했습니다.
이 주식 옵션은 Nasdaq 규칙 5635(c)(4)에 따라 부여되며, 10년의 유효 기간을 가지며 4개의 동등한 연간 할부로 분할됩니다. 행사 가격은 2025년 3월 17일 기준 Autonomix의 일반 주식의 Nasdaq 자본 시장 종가와 일치합니다. 이 부여는 직원의 보상 패키지의 일환으로 제공되었으며, 그들의 고용을 위한 유인으로 제공되었습니다.
Autonomix Medical (NASDAQ: AMIX), une société de dispositifs médicaux spécialisée dans le diagnostic et les technologies de traitement des maladies du système nerveux, a annoncé une attribution d'options d'achat d'actions en tant qu'incitation. Le Comité de Rémunération a approuvé le 17 mars 2025, des options pour acheter 7 500 actions ordinaires pour un nouvel employé non cadre.
Les options d'achat d'actions, accordées conformément à la règle 5635(c)(4) de Nasdaq, ont une durée de dix ans et seront acquises en quatre versements annuels égaux. Le prix d'exercice correspond au prix de clôture des actions ordinaires d'Autonomix sur le Nasdaq Capital Market au 17 mars 2025. L'attribution fait partie du package de rémunération de l'employé et a été fournie comme incitation à leur emploi.
Autonomix Medical (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf die Diagnostik und Behandlung von Erkrankungen des Nervensystems spezialisiert hat, hat eine Anreiz-Aktienoptionszuteilung angekündigt. Der Vergütungsausschuss genehmigte am 17. März 2025 Optionen zum Kauf von 7.500 Stammaktien für einen neuen nicht-executive Mitarbeiter.
Die Aktienoptionen, die gemäß der Nasdaq-Regel 5635(c)(4) gewährt werden, haben eine Laufzeit von zehn Jahren und werden in vier gleichen jährlichen Raten fällig. Der Ausübungspreis entspricht dem Schlusskurs der Stammaktien von Autonomix am Nasdaq Capital Market am 17. März 2025. Die Zuteilung ist Teil des Vergütungspakets des Mitarbeiters und wurde als Anreiz für deren Beschäftigung bereitgestellt.
- None.
- None.
THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on March 17, 2025 to purchase 7,500 shares of the Company’s common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual’s employment compensation and was granted as an inducement material to their start of employment with the Company.
The option has an exercise price equal to the closing price of Autonomix’s common stock as reported by the Nasdaq Capital Market on March 17, 2025. The options have a ten-year term and vest in four equal annual installments, subject to the employee’s continued services to the Company through the applicable vesting dates.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, to submit and receive approval of an IDE, and to file a De Novo application. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What are the vesting terms for AMIX's March 2025 inducement stock options?
How many shares were included in AMIX's March 2025 inducement grant?
What is the exercise price for AMIX's March 2025 inducement options?
Under which Nasdaq rule was AMIX's March 2025 stock option grant issued?
